Adjuvants: no longer a ‘dirty little secret’, but essential key players in vaccines of the future

References

• WHO, UNICEF, World Bank. State of the World’s Vaccines and Immunization (3rd Edition). World Health Organization, Geneva, Switzerland (2009).
   Google Scholar
• Plotkin S, Orenstein W, Offit P. Vaccines (5th Edition). Saunders Elsevier, PA, USA (2008).
   Google Scholar
• Mosca F, Tritto E, Muzzi A et al. Molecular and cellular signatures of human vaccine adjuvants. Proc. Natl Acad. Sci. USA105(30), 10501–10506 (2008).
   PubMed Web of Science ®Google Scholar
• De Gregorio E, Tritto E, Rappuoli R. Alum adjuvanticity: unraveling a century old mystery. Eur. J. Immunol.38(8), 2068–2071 (2008).
   PubMed Web of Science ®Google Scholar
• Harrison LC. The prospect of vaccination to prevent type 1 diabetes. Hum. Vaccin.1(4), 143–150 (2005).
   PubMed Web of Science ®Google Scholar
• Lebens M, Sun JB, Czerkinsky C, Holmgren J. Current status and future prospects for a vaccine against schistosomiasis. Expert Rev. Vaccines3(3), 315–328 (2004).
   PubMedGoogle Scholar
• McManus DP. The search for a vaccine against schistosomiasis – a difficult path but an achievable goal. Immunol. Rev.171, 149–161 (1999).
   PubMed Web of Science ®Google Scholar
• McManus DP, Loukas A. Current status of vaccines for schistosomiasis. Clin. Microbiol. Rev.21(1), 225–242 (2008).
   PubMed Web of Science ®Google Scholar
• Targett GA, Greenwood BM. Malaria vaccines and their potential role in the elimination of malaria. Malar. J.7(Suppl. 1), S10 (2008).
   Web of Science ®Google Scholar
• Birkett AJ. PATH Malaria Vaccine Initiative (MVI): perspectives on the status of malaria vaccine development. Hum. Vaccin.6(1) (2010).
   PubMed Web of Science ®Google Scholar
• Chattopadhyay R, Conteh S, Li M, James ER, Epstein JE, Hoffman SL. The effects of radiation on the safety and protective efficacy of an attenuated Plasmodium yoelii sporozoite malaria vaccine. Vaccine27(27), 3675–3680 (2009).
   PubMed Web of Science ®Google Scholar
• Hoffman SL, Billingsley PF, James E et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum. Vaccin.6(1), 97–106 (2010).
   PubMed Web of Science ®Google Scholar
• Hansen R, deSilva S, Strickland GT. Antisporozoite antibodies in mice immunized with irradiation-attenuated Plasmodium berghei sporozoites. Trans. R. Soc. Trop. Med. Hyg.73(5), 574–578 (1979).
   PubMed Web of Science ®Google Scholar
• Daar AS, Thorsteinsdottir H, Martin DK, Smith AC, Nast S, Singer PA. Top ten biotechnologies for improving health in developing countries. Nat. Genet.32(2), 229–232 (2002).
   PubMed Web of Science ®Google Scholar
• De Gregorio E, D’Oro U, Wack A. Immunology of TLR-independent vaccine adjuvants. Curr. Opin. Immunol.21(3), 339–345 (2009).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Valiante NM. Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. Drug Discov.2(9), 727–735 (2003).
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol.11(5), 373–384 (2010).
   PubMed Web of Science ®Google Scholar
• Holmgren J, Harandi AM, Czerkinsky C. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Expert Rev. Vaccines2(2), 205–217 (2003).
   PubMedGoogle Scholar
• Holmgren J, Lycke N, Czerkinsky C. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine11(12), 1179–1184 (1993).
   PubMed Web of Science ®Google Scholar
• Dagan R, Poolman J, Siegrist CA. Glycoconjugate vaccines and immune interference: a review. Vaccine28(34), 5513–5523 (2010).
   PubMed Web of Science ®Google Scholar
• Cummings JF, Spring MD, Schwenk RJ et al. Recombinant liver stage antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-γ/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection. Vaccine28(31), 5135–5144 (2009).
   PubMed Web of Science ®Google Scholar
• Waitumbi JN, Anyona SB, Hunja CW et al. Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial. PLoS ONE4(11), e7849 (2009).
   PubMed Web of Science ®Google Scholar
• Garcon N, Chomez P, Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines6(5), 723–739 (2007).
   PubMed Web of Science ®Google Scholar
• Spohn G, Bachmann MF. Exploiting viral properties for the rational design of modern vaccines. Expert Rev. Vaccines7(1), 43–54 (2008).
   PubMed Web of Science ®Google Scholar
• Moorthy VS, Ballou WR. Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malar. J.8(1), 312 (2009).
   PubMed Web of Science ®Google Scholar
• Kubler-Kielb J, Majadly F, Wu Y et al. Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25. Proc. Natl Acad. Sci. USA104(1), 293–298 (2007).
   PubMed Web of Science ®Google Scholar
• Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J.8(3), E501–E507 (2006).
   PubMed Web of Science ®Google Scholar
• Peek LJ, Middaugh CR, Berkland C. Nanotechnology in vaccine delivery. Adv. Drug Deliv. Rev.60(8), 915–928 (2008).
   PubMed Web of Science ®Google Scholar
• Arakawa T, Komesu A, Otsuki H et al. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum. Infect. Immun.73(11), 7375–7380 (2005).
   PubMed Web of Science ®Google Scholar
• Arakawa T, Tachibana M, Miyata T et al. Malaria ookinete surface protein-based vaccination via the intranasal route completely blocks parasite transmission in both passive and active vaccination regimens in a rodent model of malaria infection. Infect. Immun.77(12), 5496–5500 (2009).
   PubMed Web of Science ®Google Scholar
• Arakawa T, Tsuboi T, Kishimoto A et al. Serum antibodies induced by intranasal immunization of mice with Plasmodium vivax Pvs25 co-administered with cholera toxin completely block parasite transmission to mosquitoes. Vaccine21(23), 3143–3148 (2003).
   PubMed Web of Science ®Google Scholar
• Sun JB, Eriksson K, Li BL, Lindblad M, Azem J, Holmgren J. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells. Clin. Immunol.112(1), 35–44 (2004).
   PubMed Web of Science ®Google Scholar
• Miyata T, Harakuni T, Tsuboi T et al.Plasmodium vivax ookinete surface protein Pvs25 linked to cholera toxin B subunit induces potent transmission-blocking immunity by intranasal as well as subcutaneous immunization. Infect. Immun.78(9), 3773–3782 (2010).
   PubMed Web of Science ®Google Scholar
• Harakuni T, Sugawa H, Komesu A, Tadano M, Arakawa T. Heteropentameric cholera toxin B subunit chimeric molecules genetically fused to a vaccine antigen induce systemic and mucosal immune responses: a potential new strategy to target recombinant vaccine antigens to mucosal immune systems. Infect. Immun.73(9), 5654–5665 (2005).
   PubMed Web of Science ®Google Scholar
• Lycke N, Bemark M. Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins. Mucosal Immunol. DOI: 10.1038/mi.2010.54 (2010) (Epub ahead of print).
   Google Scholar
• Lycke N. The B-cell targeted CTA1-DD vaccine adjuvant is highly effective at enhancing antibody as well as CTL responses. Curr. Opin. Mol. Ther.3(1), 37–44 (2001).
   PubMedGoogle Scholar